Anthony Mega is an Oncology physician affiliated with Brown University. OpenAlex indexes 138 publications with 2,770 citations (h-index 24); ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
164 Summit Avenue
Fain 3
Providence, RI 029062853
Telephone
401-793-2920Registry record last updated 8 Jul 2007.
Clinical trials
- Assessment of the Effectiveness of Chemotherapy Teaching: BrUOG 258
Sponsor: Brown University
- Study of Dasatinib, Androgen Deprivation Therapy and Radiation
Sponsor: Brown University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Daiichi Sankyo Inc.Program year20251 payment
- Merck Sharp & Dohme LLCProgram year20251 payment
- Roche Diagnostics CorporationProgram year20241 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
50.2%Cytochrome P450 17A1 Inhibitor31%Abiraterone Acetate100%Part D≥54 patientsAndrogen Receptor Inhibitor7.4%Xtandi81%Bicalutamide19%Part D≥15 patients+ 4 more classes in this area
Metabolism & gastrointestinal
25%Corticosteroid22.8%Prednisone100%Part D≥50 patientsPotassium supplement2.3%Klor-Con M20100%Part D<11 patientsGenitourinary & hormones
9.8%alpha-Adrenergic Blocker6.8%Tamsulosin Hcl100%Part D≥26 patientsAndrogen3%Testosterone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
npj Precision Oncology
2025 - Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management
Urologic Oncology Seminars and Original Investigations
2024 - Adverse effects and discontinuation of pembrolizumab in BCG refractory non-muscle invasive bladder cancer.
Journal of Clinical Oncology
2024 - Evolution of the HIF targeted therapy in clear cell renal cell carcinoma
Cancer Treatment Reviews
2023
Similar KOLs
Other experts from the same institution or the same specialty.
James Klinger, MD
Brown University
Sharon Rounds, MD
Brown University
William Corrao, MD
Brown University
Eric Gartman
Brown University
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Larry Norton, MD
Memorial Sloan Kettering Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”